The Parkinson’s Disease Therapeutic Market Size is valued at USD 4.22 billion in 2023 and is predicted to reach USD 6.51 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031.
Parkinson's disease is attributed to the loss of neurons in the part of the brain responsible for motor control. The exact etiology of nerve cell degeneration remains unknown; however, it is hypothesized that exposure to environmental risk factors and genetic predisposition may play a significant role. The Parkinson's disease Therapeutic Market is witnessing robust growth, propelled by numerous key drivers and emerging opportunities.
The Parkinson's disease therapeutic market is a dynamic sector focused on developing treatments to manage the symptoms and progression of this neurodegenerative disorder. It encompasses a range of pharmaceuticals, medical devices, and therapies aimed at quality improvement of life for individuals with Parkinson's disease. Supportive care, including counselling and educational resources, is essential for both patients and caregivers. Although there is presently no remedy for Parkinson's disease, implementing these comprehensive techniques can greatly improve quality of life and effectively manage symptoms.
The overall market players consist of pharmaceutical companies, research institutions, and healthcare providers. Advances in research and technology drive innovation in treatment options, with a growing emphasis on personalized medicine and holistic approaches to care. Despite challenges such as regulatory hurdles and limited treatment options, the market continues to evolve to meet the needs of patients worldwide.
Competitive Landscape
Some Major Key Players In The Parkinson’s Disease Therapeutic Market:
- Teva Pharmaceutical Industries Ltd.,
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co. Inc.,
- Zydus Cadila
- Reddy's
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics.
- Intas Pharmaceuticals Ltd.
- Torrent Pharmaceuticals Ltd.
- Amneal Pharmaceuticals
- Aurobindo Pharma Limited
- Accord Healthcare Ltd.
- Other Market Players
Market Segmentation:
The Parkinson's disease therapeutic market is categorized on the basis of drug class, distribution channel, brand and route of administration. According to the drug class, the market is segmented into carbidopa-levodopa, dopamine agonists, Mao-b inhibitors, COMT inhibitors, anticholinergics, and others. As per the distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy.
Based On Drug Class, The Dopamine Agonists Segment Accounts For A Major Contributor To The Parkinson's Disease Therapeutics Market.
The dopamine agonists segment in the Parkinson's disease therapeutic market comprises a class of medications that mimic the action of dopamine in the brain to alleviate motor symptoms of the disease. These drugs stimulate dopamine receptors, helping to improve movement control and reduce tremors and rigidity in patients with Parkinson's disease. Common dopamine agonists include pramipexole and ropinirole. While effective in managing symptoms, these medications may also be associated with side effects such as nausea, dizziness, and hallucinations. Despite challenges, dopamine agonists play a crucial role in the treatment regimen for many individuals living with Parkinson's disease.
The Hospital Pharmacy Segment Witnessed A Rapid Growth.
The hospital pharmacy segment of the Parkinson's disease therapeutic market focuses on providing medications and pharmaceutical services within hospital settings to manage the complex treatment needs of patients with Parkinson's disease. Hospital pharmacies play a important role in ensuring the availability, proper dosing, and administration of medications such as levodopa, dopamine agonists, and other therapies used to alleviate symptoms & improve the quality of life for individuals with Parkinson's disease. These pharmacies also collaborate with healthcare teams to monitor drug interactions, adjust treatment regimens, and optimize medication adherence to enhance patient outcomes and safety during hospitalization and post-discharge care.
In The Region, The North American Parkinson's Disease Therapeutic Market Holds The Major Share Of The Market.
The North American Parkinson's disease therapeutic market is a significant sector characterized by a high prevalence of the disease and a strong focus on research, innovation, and healthcare infrastructure. The region comprises leading pharmaceutical companies, research institutions, and healthcare providers dedicated to developing and delivering advanced treatments for Parkinson's disease. With a growing ageing population and increasing awareness of neurological disorders, the market in North America continues to expand, offering various medications, therapies, and support services to direct the complex needs of patients. Ongoing advancements in treatment options and patient care contribute to shaping the landscape of Parkinson's disease management in North America. Asia Pacific is counted to grow at a rapid rate in the global Parkinson's disease Therapeutic Market due to growing concerns about rapid industrialization, government initiatives, and increasing funding in various industries.
Recent Developments:
- In March 2024, Sanofi and Cipla have formed an exclusive collaboration to distribute and promote Sanofi India'sIndia's Central Nervous System (CNS) product range in India. Under this collaboration, Cipla will assume the responsibility of distributing Sanofi India'sIndia's six CNS brands, which includes Frisium®, a prominent brand in the anti-epileptic drug field.
- In Oct 2022, Biogen and Denali Therapeutics commenced the Phase 3 LIGHTHOUSE Study in Parkinson'sParkinson's Disease linked to LRRK2 Pathogenic Mutations. The main objective of the LIGHTHOUSE trial was to measure the duration until proven deterioration, evaluated using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson'sParkinson's Disease Rating Scale (MDS-UPDRS), during the treatment term of up to 180 weeks.
Parkinson’s Disease Therapeutic Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.22 Bn |
|
Revenue Forecast In 2031 |
USD 6.51 Bn |
|
Growth Rate CAGR |
CAGR of 5.7% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class, Distribution Channel, Brand And Route Of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy's, Sun Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., Biogen Inc., Prevail Therapeutics and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
